Form 4 for TRAW Traws Pharma, Inc.
Accepted 2026-04-08 14:47:50 ET · period of report 2025-10-12 · accession 0002125562-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-04-08 14:47 | 2025-12-12 | TRAW | Parker Charles Nolan | CFO | A - Grant | $0.00 | +15.4K | 15.4K | New | $0 |
| DM | 2026-04-08 14:47 | 2025-10-12+ | TRAW | Parker Charles Nolan | CFO | A - Grant | $0.00 | +198.5K | 104.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-12 | A | A | 15,393 | $0.00 | 15,393 | D | — | — | (F1) Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis. |
| 2 | Derivative | Stock Option (right to buy) | 2025-10-12 | A | A | 32,406 | $0.00 | 32,406 | D | $3.01 · 2026-10-12 to 2035-10-12 | 32,406 Common Stock | (F2) Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date. |
| 3 | Derivative | Stock Option (right to buy) | 2025-12-12 | A | A | 61,571 | $0.00 | 61,571 | D | $2.33 · 2026-12-12 to 2035-12-12 | 61,571 Common Stock | (F3) Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date. |
| 4 | Derivative | Stock Option (right to buy) | 2026-03-08 | A | A | 104,544 | $0.00 | 104,544 | D | $1.60 · 2027-03-08 to 2036-03-08 | 104,544 Common Stock | (F4) Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date. |